Our Company

Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis.  Founded in 2012 by NetScientific plc on technology originating at the Baruch S. Blumberg Institute and Drexel University College of Medicine, we have exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers that exploit novel sugar-based disease signals.  The Company’s lead test for curable early-stage liver cancer has significantly outperformed the current standard blood test in multiple preliminary clinical studies.  Our mission is to revolutionize the care and treatment of the at-risk chronic liver disease population, including the rapidly growing population with NASH.


Glycotest was created in 2012 based on technology developed by two experts in the fields of liver disease and glycobiology-Professors Timothy Block and Anand Mehta at Drexel University College of Medicine and the Baruch S. Blumberg Institute. Glycotest has the exclusive worldwide rights to the use of over 50 patented serum glycoprotein biomarkers whose sugar structures are altered in liver cancers and fibrosis-cirrhosis by the abnormal attachment of the monosaccharide fucose.

First Test–HCC Panel for Early Detection

Our first test is the HCC Panel which is designed for the early detection of Hepatocellular Carcinoma (HCC). The HCC Panel is a surveillance test for patients who have had chronic liver disease and are at a higher risk of getting HCC. If HCC is detected early, it can be curable, but unfortunately, current test methods are not sensitive enough to catch most early-stage HCC. The HCC Panel test is currently being used in a 476 patient clinical validation study which we expect will be completed in mid-2020. We are planning to launch the HCC Panel to hepatologists late next year through our CLIA lab.


Management Team and Board

  • John Clarkson

    John Clarkson, Non-Executive Chairman of NetScientific, is an experienced business professional and qualified accountant, who had a successful early career working in various financial,…
  • Ilian Iliev PhD

    Dr. Ilian Iliev joined the Net Scientific Board in 2019 and became CEO in 2020. He is also Managing Director of EMV Capital (EMVC)…
  • Charles Swindell

    Charles Swindell has over 30 years of experience in biopharmaceutical R&D, product development, and senior management in entrepreneurial life science companies.   He has…
  • Professor Stephen Smith

    Professor Stephen Smith, Non-Executive Director, joined the NetScientific Board in 2016. Stephen has held senior leadership roles in the NHS and academia. He has…
  • Ms. Pei JIANG

    Ms. Pei JIANG graduated with Master degree of lmmunology from Fudan University in 2012. She joined Shanghai Fosun Long March Medical Science Co., Ltd…
  • Ms. Lily ZOU

    Ms. Lily ZOU is President and CEO of Fosun Pharma USA, where she is responsible for building and growing Fosun Pharma's US business. Fosun…

Scientific and Medical Advisors


NetScientific UK Ltd.

About NetScientific UK Ltd.

NetScientific identifies, develops and commercializes transformative biomedical and healthcare technologies originating from leading universities, teaching hospitals and research institutes, with a focus on United Kingdom and United States.

More information about NetScientific’s purpose, core strategy and investment model are available at netscientific.net


Fosun Pharma

About Fosun Pharma

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of the healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices, and medical diagnosis, as well as pharmaceutical distribution and retail. Fosun Pharma always regards innovation as the driving force for its business growth.

More information about Fosun Pharma
click:  www.fosunpharma.com 


Baruch S. Blumberg Institut

About Blumberg Institut

The Baruch S. Blumberg Institute is an independent, nonprofit (501c3) research institute established in 2003 by the Hepatitis B Foundation to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. It is particularly focused on discovery of new therapeutics to manage chronic hepatitis B and liver cancer, and early detection of liver disease. Working with academic partners, its scientists have pioneered discovery of new strategies to manage chronic hepatitis B and to detect liver cancer. It was renamed in 2013 to honor Baruch S. Blumberg, who won the Nobel Prize for his discovery of the hepatitis B virus and co-founded the Hepatitis B Foundation. The Baruch S. Blumberg Institute created and manages the Pennsylvania Biotechnology Center, one of the nation’s leading incubators for life sciences startup companies..

More information about Blumberg Institut
click: www.blumberginstitute.org


A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

ABOUT US | Glycotest Diagnostics